Alzheimer's disease progression model using disability assessment for dementia scores from bapineuzumab trials
{{output}}
Objective: Disability assessment for dementia (DAD) measurements from two phase-3 studies of bapineuzumab in APOE ε4 noncarrier and carrier Alzheimer's disease (AD) patients were integrated to develop a disease progression model... ...
